Results 1 to 10 of about 476 (121)
DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS [PDF]
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj +3 more sources
ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ [PDF]
Высокая распространенность тромботических осложнений у пациентов с сердечно-сосудистыми заболеваниями обусловила широкое применение в клинической практике антикоагулянтной терапии. Длительное время основным антикоагулянтом, применяемым по этим показаниям,
О. Шахматова О.
doaj +3 more sources
Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin +2 more
doaj +1 more source
In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva +2 more
doaj +1 more source
Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients ...
A. S. Kolbin +2 more
doaj +1 more source
В обзорной статье рассмотрены результаты наблюдательного когортного исследования Medicare, целью которого являлось получение дополнительной информации об эффективности и безопасности дабигатрана у более чем 130 тыс.
Н. М. Воробьева +1 more
doaj +1 more source
Эффективность и безопасность апиксабана: что изменилось за 12 лет его использования в реальной клинической практике? [PDF]
This review examines the position of apixaban among other direct oral anticoagulants in patients with atrial fibrillation (AF) and venous thrombosis in randomized clinical trials and real clinical practice.
E. Р. Panchenko +1 more
core +2 more sources
Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj +1 more source
Prognosis and prevention of cardioembolic stroke in patients with atrial fibrillation
The article is a review of literature on the prognosis and prevention of stroke in patients with atrial fibrillation (AF). It is noted that the simple CHA2DS2-VASc calculator is a good predictor of the risk of stroke in AF.
V. А. Parfyonov, S. V. Verbitskaya
doaj +1 more source
Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease [PDF]
Atrial fibrillation (AF) is the most common cardiac arrhythmia, which is associated with an increased risk of cardiovascular death. The latter is partly due to the common combination with coronary artery disease (CAD). If indicated, patients with AF need
A. A. Shavarov, Zh. D. Kobalava
core +2 more sources

